Munich, Germany and Montreal, Quebec, Canada (October 30, 2024) – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will host a series of sessions focused on the critical role artificial intelligence (AI) plays in the future of the biopharma industry at BIO-Europe 2024 in Stockholm, Sweden. Taking place on Tuesday, November 5th, this AI track will gather leading industry experts and innovators to discuss how AI is reshaping drug discovery and development, diagnostics, patient care and more.

“AI is fundamentally transforming the biopharma industry and all aspects of healthcare. At BIO-Europe 2024, we are bringing together some of the brightest minds in this field to explore the tangible benefits and future potential of AI technologies. These sessions not only will highlight the latest advancements but also provide a platform for discussing the challenges and opportunities that lie ahead. The future of healthcare will be driven by AI, and this event is an opportunity to be part of that conversation,” said Dr. Hubert Birner, Managing Partner, TVM Capital Life Science.

Keynote Session: “Indestructible”: Why is AI Crucial for the Future of the Biopharma Industry?
Date and Time: Tuesday, November 5th, 15:30 – 16:00 CET, Room K1

This keynote session, led by Verena Schustereder, Customer Engineer Manager, EMEA North at Google Europe, will provide a deep dive into AI’s transformative impact on healthcare and biopharma. Attendees will gain insights into how AI is revolutionizing research, development and patient care, setting the stage for the future of medicine. Schustereder will offer a unique perspective on the profound implications of AI for the biopharma industry, covering its potential to enhance efficiency, innovation and patient outcomes.

Moderators:  
Hubert Birner, Managing Partner, TVM Capital Life Science                                                                                                                    
Denis Dubuy, Director of Corporate Development, Owkin

Session 1: “I Have a Dream”: AI for Drug Discovery
Date and Time: Tuesday, November 5th, 16:00 – 16:45 CET, Room K1

In this session, industry experts will explore how AI is accelerating drug discovery processes, from target identification to the development of novel therapeutics. By applying AI-driven solutions, companies are dramatically speeding up timelines and enhancing the precision of their research. Attendees will hear from prominent figures in the field as they share real-world case studies, the latest advancements, and ongoing challenges in the application of AI in drug discovery.

Moderator: Maria Luisa Pineda, CEO and Co-Founder, Envisagenics
Speakers:

• Rogier Rooswinkel, General Partner, Forbion
• Hartmut Juhl, CEO and Founder, Indivumed Therapeutics
• Lovisa Afzelius, General Partner, Flagship Pioneering
• Tim James, VP, Head of In Silico R&D, Evotec
• Michelle Chen, CBO, Insilico Medicine
• Stephan Brock, CTO, Molecular Health
• Nikolas Krall, EVP Precision Medicine, Exscientia

Session 2: “Why Did It Have to Be Me?”: AI for Diagnosis
Date and Time: Tuesday, November 5th, 16:45 – 17:30 CET, Room K1

This session will focus on AI’s role in revolutionizing medical diagnostics. Experts will discuss how AI-powered diagnostic tools are enhancing accuracy, speeding up diagnosis and ultimately improving patient outcomes. The discussion will also touch on challenges and opportunities in integrating AI into existing diagnostic frameworks, offering a glimpse into the future of personalized medicine.

Moderator: Bora Erdemli, Partner ZS
Speakers:

• Ralf Huss, CEO, BioM
• David Krummen, Co-Founder, Vektor Medical
• Andrea Gisle Joosen, Board Member, Zühlke Group
• Miha Stajdohar, CTO, Genialis
• Andrea Riposati, CEO, Dante Omics

These sessions offer a rare opportunity for industry professionals, innovators and investors to explore the intersection of AI and biopharma and better understand how cutting-edge technologies are driving the future of healthcare.

To learn more about the sessions and schedule meetings, please reach out via the partneringONE system.

About TVM Capital Life Science
TVM is a leading international venture capital firm focused on investing in life science innovations.  The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care.

TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

With its late-stage investments, TVM focuses on differentiated medical technologies and health tech with commercial proof-of-concept, as well as late-stage therapeutics expected to quickly reach major development or regulatory milestones. This strategy has been validated through a number of companies in both Fund I and II and the Colucid Pharmaceuticals exit.

The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

For further information, please visit www.tvm-capital.com. Follow TVM on LinkedIn.

TVM and Portfolio Companies Showcase Transformative Partnerships and Industry Trends in Panel discussions and Presentations

Munich, Germany and Montreal, Quebec, Canada (September 11, 2024) – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will participate in the annual LSI Europe ’24 Emerging Medtech Summit 2024. This prestigious event brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies. The conference will take place September 16-20, 2024, in Sintra, Portugal at Penha Longa, The Ritz Carlton.

“Medtech innovation continues to be at the forefront of healthcare advancement, driving transformative changes in patient care, operational efficiency and cost reduction. As part of our commercial-stage medical technologies investment strategy, TVM seeks breakthrough solutions that align with emerging trends and could redefine the standard of care. We look forward to engaging with fellow industry leaders at this year’s European Emerging Medtech Summit and to exploring new opportunities with innovative entrepreneurs that could further enrich our portfolio,” said Dr. Luc Marengère, Managing Partner.

Dr. Hubert Birner, Managing Partner added, “The rapid advancements in medtech are creating unprecedented opportunities to address unmet clinical needs. At TVM, we are dedicated to supporting visionary companies that are pioneering transformative healthcare solutions. Our participation in LSI Europe ’24 underscores our commitment to fostering innovation and forging strategic partnerships that can shape the future of medicine.”

TVM pursues a unique two-pronged strategy, investing in differentiated medical technologies with commercial proof-of-concept and late clinical-stage therapeutics as well as financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC). With its late-stage medtech investments, the Company focuses on innovative businesses from North America and the EU working to transform medical practice with their groundbreaking devices and technologies.

TVM panel participation:

• Luc Marengère – Building Syndicates of Cross-Border Investors in Medtech Companies
  September 17^th | 15:35 CET | Track 1

The following companies from TVM’s medtech commercial-stage portfolio will present at the summit:

• Kent Imaging, develops, manufactures and markets medical technology that supports real-time decision-making in wound care and vascular and surgical subspecialties and tracks the healing process. The company targets limb preservation and reconstructive surgical markets – areas with clear unmet need, as non-healing wounds are a major burden to patients and the healthcare system.
  
  
• Vektor Medical, has developed and is commercializing an AI-based, non-invasive arrhythmia analysis technology, vMap, that enables physicians to pinpoint source locations rapidly and accurately for both focal and fibrillation-type arrhythmias. The company aims to improve cardiac ablation outcomes, optimize workflows and increase procedural efficiency.

About TVM Capital Life Science
TVM is a leading international venture capital firm focused on investing in life science innovations.  The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care.

TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

With its late-stage investments, TVM focuses on differentiated medical technologies and health tech with commercial proof-of-concept, as well as late-stage therapeutics expected to quickly reach major development or regulatory milestones. This strategy has been validated through a number of companies in both Fund I and II and the Colucid Pharmaceuticals exit.

The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

For further information, please visit www.tvm-capital.com. Follow TVM on LinkedIn.

Munich, Germany and Montreal, Quebec, Canada, April 22, 2024 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced the successful closing of a €23 million Series C financing round for Smart Reporting, a pioneer and market leader in the field of medical reporting, particularly in radiology and pathology. TVM led the round, supported by Bayern Kapital and existing investors. The proceeds will be used primarily to expand international partnerships and product development and, in particular, to strengthen the company’s market presence in the US, Canada, Australia and New Zealand. Dr. Hubert Birner, Managing Partner at TVM, will join the Smart Reporting Board of Directors, and Stefan Fischer, Managing Partner (Finance), will serve as a Board Observer.

Medical documentation makes up to 40% of a physicians’ daily workload. Previously, this was mostly a manual process. Smart Reporting automates and streamlines this workflow and creates valuable data in the process; this is particularly important at a time when the number of radiologists is decreasing. The company’s groundbreaking medical documentation technology – “SmartReports” – delivers high-quality data in real-time and at any scale. This manufacturer-independent software offers a fully voice-controlled and data-driven documentation solution for doctors that forms the basis for workflow automation and machine-readable data. Smart Reporting thus provides a crucial module for digitalization in the hospital sector. In addition, Smart Reporting recently intensified its partnership with Solventum (formerly 3M Health Information Systems), one of the market leaders in the field of radiology reporting in North America, to further strengthen its presence in international markets. The collaboration provides customers access to additional cutting-edge technologies and innovation that will make radiology reporting even more time-efficient and data-driven. The software is distributed internationally via major healthcare IT partners, including Siemens Healthineers, GE Healthcare and Canon.

Dr. Hubert Birner, Managing Partner at TVM Capital Life Science, said: “New technologies such as AI and machine learning are key drivers of innovation in the healthcare industry and offer great potential for growth. TVM sees Smart Reporting, with their groundbreaking technology, already used by thousands of doctors around the globe, as one of the future international market leaders in the areas of radiology and pathology. Also, the breadth of their partnerships with leading corporations in the radiology sector is impressive.”

“As an international venture capitalist in the life sciences, TVM finances innovative health tech and medical technologies in addition to traditional therapeutic drug development,” added Stefan Fischer, Managing Partner at TVM Capital Life Science. “The focus here is on differentiated business models of companies that are already commercially viable and create a direct benefit for patients with their technology. Smart Reporting fits perfectly into this investment strategy.”

Prof. Dr. Wieland Sommer, founder and Co-CEO of Smart Reporting, noted: “We are very pleased about the successful financing round and are grateful to TVM and our other investors for their strong support. With the additional capital, we will be able to consistently pursue our international growth strategy, which we recently launched with our market entry in the USA. Our focus in the coming months will be on further penetrating key global healthcare IT markets with our novel AI-based solutions.”

About Smart Reporting

Smart Reporting was founded in 2014 by Wieland Sommer, Professor of Radiology with a Master’s degree in public health (Harvard, US). The company was established in Munich with the vision of harnessing the value of medical data for better decision-making and treatment. Today, it has an interdisciplinary team of more than 80 doctors, data scientists and software engineers from Germany, Austria, Switzerland and Brazil who develop software based on their detailed understanding of clinical workflows. The company’s multilingual software for structured diagnostics in radiology and pathology is used by more than 16,000 physicians in over 90 countries. www.smart-reporting.com

About TVM Capital Life Science

TVM is a leading international venture capital firm focused on investing in life science innovations. The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care.

TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

For further information, please visit www.tvm-capital.com. Follow TVM on LinkedIn.

TVM and Portfolio Companies Showcase Transformative Partnerships and Industry Trends in Panel discussions and Presentations

Munich, Germany and Montreal, Quebec, Canada (March 13, 2024) – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will participate in the sixth annual LSI USA ’24 Emerging Medtech Summit 2024, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies. The conference will take place March 18-22, 2024, in Dana Point, California, USA.  

“Medtech innovation continues to be at the forefront of healthcare advancement, driving transformative changes in patient care, operational efficiency and cost reduction. As part of our commercial-stage medical technologies investment strategy, TVM seeks breakthrough solutions that align with emerging trends and could redefine the standard of care. We look forward to engaging with fellow industry leaders at this year’s Emerging Medtech Summit and to exploring new opportunities with innovative entrepreneurs that could further enrich our portfolio,” said Dr. Luc Marengère, Managing Partner.

TVM pursues a unique two-pronged strategy, investing in differentiated medical technologies with commercial proof-of-concept and late clinical-stage therapeutics as well as financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages TVM’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. With its late-stage medtech investments, the Company focuses on innovative businesses from North America or the EU working to transform medical practice with their groundbreaking devices and technologies.

Dr. Sascha Berger, General Partner, emphasized: “Amidst the current hype surrounding artificial intelligence, it’s highly gratifying to participate in investments that embody the true transformative potential of AI in healthcare. These technologies have the capability to revolutionize how healthcare is delivered, making it accessible and personalized. Medtech and AI present exciting opportunities for investors who are willing to navigate this rapidly evolving landscape. Our successful track record of collaborations in medical technologies underscores our commitment to foster partnerships and add value to cutting edge innovative ventures.”

TVM Participation:

• Luc Marengère – The End of One Road and the Beginning of Another: Transitioning from Pre to Post FDA
  March 20^th | 5:10-5:50 pm PST | Track 2

• Sascha Berger – Advent of AI: What Will it Take to Drive True Adoption in Clinical Workflows?
  March 20^th | 1:30-2:10 pm PST | Track 3

The following companies from TVM’s medtech commercial-stage portfolio will present at the summit:

• Access Vascular, has developed and is commercializing award-winning intravenous catheters addressing the most common and costly complications of intravenous therapy: infection, thrombosis, and phlebitis. Engineered to mimic the body’s natural chemistry, Access Vascular catheters are designed to evade foreign body response and related complications.
  
  
• Egg Medical, has developed and is commercializing a lab radiation protection system that dramatically reduces scatter radiation exposure during interventional angiographic procedures. During an X-ray, radiation reflects off a patient and scatters to anyone else in the room, resulting in an increased risk of cancer chromosomal abnormalities, skin damage and eye injury for healthcare professionals. EGGNEST™ reduces scatter radiation exposure by 91% for the entire team without interrupting the workflow.
  
  
• Kent Imaging, develops, manufactures, and markets medical technology that supports real-time decision-making in wound care, vascular and surgical subspecialties and tracks the healing process. The company targets limb preservation and reconstructive surgical markets – areas with clear unmet need, as non-healing wounds are a major burden to patients and the healthcare system.
  
  
• Vektor Medical, has developed and is commercializing an AI-based, non-invasive arrhythmia analysis technology, vMap, that enables physicians to pinpoint source locations rapidly and accurately for both focal and fibrillation-type arrhythmias. The company aims to improve cardiac ablation outcomes, optimize workflows and increase procedural efficiency.

About TVM Capital Life Science

TVM is a leading international venture capital firm focused on investing in life science innovations.  The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care.

TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

With its late-stage investments, TVM focuses on differentiated medical technologies and health tech with commercial proof-of-concept, as well as late-stage therapeutics expected to quickly reach major development or regulatory milestones. This strategy has been validated through a number of companies in both Fund I and II and the Colucid Pharmaceuticals exit.

The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

For further information, please visit www.tvm-capital.com. Follow TVM on LinkedIn.

Munich, Germany and Montreal, Quebec, Canada, February 6, 2024 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced a $16 million Series A financing for Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology. TVM is co-leading the round with Solas BioVentures. The proceeds will be used to support the commercialization of vMap®, Vektor’s AI-based arrhythmia analysis tool, which is transforming how electrophysiologists (EPs) approach ablation procedures. Dr. Luc Marengère, Managing Partner at TVM, will join the Vektor Medical Board of Directors, and Dr. Sascha Berger, General Partner at TVM, will serve as a Board Observer.

Vektor’s vMap is the only FDA-cleared, non-invasive AI-based solution for arrhythmia localization and analysis, seamlessly leveraging only a 12-lead ECG. vMap provides information to better understand arrhythmia source(s) enabling physicians to streamline their procedures and more efficiently treat their patients.

Dr. Luc Marengère, Managing Partner at TVM Capital Life Science, said: “Changing the standard of care demands a unique and transformative approach. vMap has been embraced by EPs focused on excellence. With increased resources, Vektor will scale adoption across the US and Europe. Patients and healthcare providers deserve better and Vektor is ushering in that transition. We’re thrilled to invest and partner with Vektor to drive this important healthcare transformation.”

“The medical community is being confronted with the necessity for change. With an increasing atrial fibrillation (AF) patient population, outcomes must be improved while also enhancing procedure efficiency,” said Rob Krummen, CEO of Vektor Medical. “vMap presents a solution to this challenge. Leading EPs around the U.S. are utilizing vMap to streamline ablation procedures and improve patient outcomes. With the proceeds from this financing, we can expand access to this groundbreaking technology.”

About Vektor Medical

Headquartered in San Diego, Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-based, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. For more information about vMap and Vektor Medical, please visit www.vektormedical.com

Follow Vektor Medical: LinkedIn and Twitter/X.

About TVM Capital Life Science

TVM is a leading international venture capital firm focused on investing in life science innovations.  The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care.

TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

With its late-stage investments, TVM focuses on differentiated medical technologies and health tech with commercial proof-of-concept, as well as late-stage therapeutics expected to quickly reach major development or regulatory milestones. This strategy has been validated through a number of companies in both Fund I and II and the Colucid Pharmaceuticals exit.

The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

For further information, please visit www.tvm-capital.com. Follow TVM on LinkedIn.

Munich, Germany and Montreal, Quebec, Canada (January 31, 2024) – TVM Capital Life Science (“TVM”), a leading transatlantic venture capital firm focused on investments in life sciences innovation, today announced the closing of a Series A financing round for Myosotis GmbH (“myo”), a pioneering Berlin-based digital healthcare startup. TVM led the round, investing €8 million. The proceeds will be used to further grow the business in the DACH region as well as in the UK. This will include expanding marketing capacity and enhancing service quality for existing customers, as well as developing new modules. Dr. Sascha Berger, General Partner, and Stefan Fischer, Managing Partner (Finance) of TVM, will join the myo Board of Directors.   

myo was founded in 2018 with the goal of relieving employees in care homes through digital solutions and bringing more transparency, participation and appreciation to the sector. The company’s communication app enables care facilities, families and service providers to communicate with each other easily, quickly and digitally. Families are able to participate in their loved ones’ everyday lives by receiving pictures, videos and documents as well as making video calls. Additional modules for the app simplify important but time-consuming administrative tasks, including ordering meals, monitoring complaints, and managing key external services such as laundry providers and pharmacies. This saves time and money and improves documentation. myo services approximately 400 customers in the DACH region and the UK.

Dr. Sascha Berger, General Partner of TVM Capital Life Science, commented: “At TVM, we are committed to advancing healthcare innovations that address unmet needs. Digital tools offer the promise of significantly increasing the efficiency of the healthcare system and giving medical professionals more time to do what they do best – care for their patients.  myo’s unique approach to elderly care communication could transform this crucial and growing sector, contributing to improved communication amongst healthcare staff, relatives and service providers, resulting in better care.”

Stefan Fischer, Managing Partner (Finance) of TVM Capital Life Science, noted: “The new digitalization strategy of Germany’s Ministry of Health not only acknowledges the incredible potential of digital solutions for the future of our under-pressure healthcare system, it also opens the way for groundbreaking technologies like myo’s apps to be integrated in a meaningful way into patient care. TVM is excited to see this important product rolled out in the DACH region and the UK. myo’s dynamic management team is well positioned to effectively scale myo’s innovative platform and make a tangible impact on the healthcare industry.”

Jasper Böckel, CEO of myo, added: “This funding is an important step in our growth plan. We are delighted to have such a well-regarded investor as TVM come on board and look forward to leveraging their experience with commercial-stage life science companies. Our passionate team is dedicated to enhancing human interactions in care settings, and these proceeds will now enable us to roll out our technology to more users and develop additional solutions for healthcare providers and families.”

About myo

Myosotis GmbH (Latin for forget-me-not flower) offers the first software-as-a-service solution for direct digital communication between employees, relatives and the ecosystem of service providers in care homes. The app enables intuitive communication with relatives through photos, videos, voice messages and video calls. This makes the impressive work in care more visible and simplifies administrative processes at the same time. The majority of communication – whether with relatives or third-party providers – can be handled by a single digital application. With just one click, homes can inform all relatives about new hygiene measures, for example, let a family participate in the life of the person in need of care and inform the doctor, pharmacy or external laundry service. This saves employees valuable time, which in turn can be used for caring for the elderly.

myo is already working with over 400 customers in DACH and the UK, including the most well-known providers, such as DRK, AWO, Johanniter and Agaplesion. Last year alone, over 30,000 users sent seven-figure interactions via the platform. In addition, interfaces have already been established with market leaders such as apetito, Sanacorp and CWS to further simplify communication for facilities.

In addition to new investors, TVM and Twip, existing shareholders include the nursing home operators Agaplesion and Carpe Diem, as well as the venture capital funds BonVenture, Axel Springer Plug & Play, Think Health, Mountain Partners, Round Hill Ventures and Capacura.

About TVM Capital Life Science

TVM is a leading international venture capital firm focused on investing in life science innovations.  The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care.

TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

With its late-stage investments, TVM focuses on differentiated medical technologies and health tech with commercial proof-of-concept, as well as late-stage therapeutics expected to quickly reach major development or regulatory milestones. This strategy has been validated through a number of companies in both Fund I and II and the Colucid Pharmaceuticals exit.

The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

For further information, please visit www.tvm-capital.com. Follow TVM on LinkedIn.

Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis

Novel antibody specifically designed for oral administration utilizes Tillotts Pharma’s sustained release approach to ensure optimal and local treatment

Mage Biologics is the 10^th early-stage or project focused company (PFC) investment for TVM Life Science Innovation II Fund

Montreal, Canada / Munich, Germany / Rheinfelden, Switzerland – 20 July 2023 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, together with specialty pharma company, Tillotts Pharma (“Tillotts”), today announced that the companies will jointly invest up to USD 28 million in the newly formed U.S.-based biotechnology company, Mage Biologics Inc. (“Mage Bio”). TVM will invest with its fund TVM Life Science Innovation II SCSp (“TVM LSI II”) and will provide strategic advice to Mage Bio, with Dr. Sascha Berger, General Partner, joining the Board of Directors and Dr. Ivan Shaw, Principal, serving as a Board Observer. Mage Bio is the 10^th early-stage or project-focused company (PFC) investment for TVM LSI II.

Mage Biologics plans to advance to clinical proof of concept a novel, orally administered, humanized monoclonal antibody (mAb) bioengineered for optimal potency and tissue penetration. The mAb has been developed by Tillotts and originated from a discovery collaboration with Swiss biotech company Numab Therapeutics. Utilizing Tillotts’ innovative sustained release approach, the antibody is designed to enable release of the drug in the appropriate area of the intestinal tract at a predetermined rate to address inflammation locally and optimally. Initially, the drug will be developed for the treatment of ulcerative colitis. Manufacturing of clinical-grade material is planned to start in 2023, with the goal of filing a clinical trial application in 2024.

Thomas A. Tóth von Kiskér, CEO and Board Director of Tillotts, commented: “We are excited to team up with TVM Capital Life Science to advance this oral antibody in ulcerative colitis, a lifelong disease profoundly impacting the patients’ quality of life. The collaboration with TVM underpins Tillotts’ leading role in developing and commercializing innovative products in the gastrointestinal field.”

“TVM Capital Life Science is proud to have enabled the creation of Mage Biologics. This investment is again a testament to our strong international network and builds on our successful single asset focus for innovative preclinical therapeutic agents,” said Sascha Berger, General Partner of TVM Capital Life Science and Member of the Board of Mage Biologics. “We are pleased to collaborate with the experienced management team of Johannes Spleiss and Chantal Miklosi, who will act as CEO and CFO, respectively, for Mage Biologics.”

Johannes Spleiss, Head of Scientific Affairs at Tillotts and CEO of Mage Biologics, added: “We are taking a new and potentially disruptive approach to overcome the challenges with traditional ulcerative colitis treatments with this oral antibody. Developing more efficacious therapies with a greater likelihood of success and less systemic side effects is an important step in continuing to innovate for the many patients living with this condition. I look forward to advancing our antibody to clinical proof of concept.”

About ulcerative colitis
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) that impacts millions of people worldwide. Ulcerative colitis affects the innermost lining of the colon and the rectum, causing inflammation and ulcers in the digestive tract. In most people, symptoms usually develop over time, taking a relapsing-remitting course, which means that periods of flare-ups are followed by periods of remission. This can be draining and, in some cases, lead to life-threatening complications. While there is no known cure, current treatments aim to reduce signs and symptoms of the disease and bring remission. Over the last decade, biologics have gained an important place in the treatment of ulcerative colitis, with several monoclonal antibodies available as subcutaneous or intravenous therapies approved for use in UC. Unfortunately, a substantial proportion of patients do not respond, lose response, or develop intolerance to currently marketed products, leading to a substantial unmet medical need for safer, effective, and more convenient therapeutic options.

About the project-focused company (PFC)
For its PFC investments, TVM has a unique arrangement with Eli Lilly and Company (“Lilly”), which is a limited partner in TVM LSI II and the earlier fund TVM LSI I, under which TVM and its PFCs have the option to engage Chorus, a full-service autonomous research and development unit within Lilly, to assist the PFC by implementing a lean and focused drug development plan, resulting in high-quality data packages to help determine proof of concept.

About Tillotts Pharma
Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with close to 400 employees in Switzerland and abroad. Tillotts is dedicated to the development, acquisition and commercialization of innovative pharmaceutical products for the digestive system. Tillotts successfully markets its own products for the treatment of IBD and Clostridioides difficile infection (CDI) as well as in-licensed products in around 65 countries through its affiliates within Europe and a network of partners throughout the world. 

About TVM Capital Life Science
TVM Capital Life Science is a leading international venture capital firm focused on investing in life science innovations. The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care. TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics. With its early-stage investments, TVM follows several key principles, which include increasing capital efficiency, streamlining development timelines and soliciting buyer input at the time of investment.  This strategy has been validated through successful exits such as AurKa Pharma, Inc. and Acanthas Pharma, Inc. The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

About Mage Biologics Inc.
Mage Biologics is a special purpose company created to develop a novel, orally administered monoclonal antibody to clinical proof of concept for the treatment of ulcerative colitis. Mage Biologics is jointly funded by TVM Life Science Innovation II and Tillotts Pharma and is led by an experienced management team.

This press release contains forward-looking statements about TVM Life Science Innovation II’s investment in a preclinical stage compound to treat certain types of gastrointestinal diseases that Mage Biologics Inc is developing. It reflects TVM’s current beliefs.

Media Relations

TVM
MC Services AG
Europe: Anne Hennecke
Tel: +49 211 529 252 22
North America: Laurie Doyle
Tel: +1 339 832 0752
Email: tvm@mc-services.eu

Tillotts Pharma
Niclas Berg, Lead Corporate Communications
Phone: +46 722 48 46 26
Email: niclas.berg@tillotts.com

Company highlights key investments from its commercial-stage medtech portfolio

Montreal, Canada / Munich, Germany – 17 March 2023 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that Dr. Luc Marengère, Managing Partner, and Dr. Sascha Berger, General Partner of TVM, will participate in the upcoming LSI USA ’23 Emerging Medtech Summit 2023, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies. The conference will take place March 20-23, 2023, in Dana Point, California, USA.

“Medtech innovation plays a pivotal role in the healthcare ecosystem and has the potential to revolutionize the industry by improving patient outcomes, increasing efficiency, and reducing costs. One key component of our strategy is to invest in disruptive, breakthrough, commercial-stage technologies that map essential future trends and significantly transform current standard-of-care. In addition to connecting with fellow investors and dealmakers to discuss market opportunities and needs, we look forward to meeting young, highly innovative companies at the LSI Summit to further expand TVM’s strong medtech portfolio,” said Dr. Luc Marengère.

TVM pursues a unique two-pronged strategy, investing in differentiated medical technologies with commercial proof-of-concept and late clinical-stage therapeutics as well as financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages TVM’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. With its late-stage medtech investments, the Company focuses on innovative businesses from North America or the EU working to transform medical practice with their groundbreaking devices and technologies.

Dr. Sascha Berger added: “TVM’s track record of successful collaboration highlights our partnership and value-building approach with innovators. As true partners, we work closely with our portfolio companies, striving to understand their ideas, and find ways to advance their innovations to accelerate growth, facilitate market expansion and ultimately help them become or continue to be a leader in their respective markets. With our current fund TVM Life Science Innovation II, we continue to expand our strategy, that has been validated through a number of companies in both Fund I and II, to build a portfolio of differentiated products with strong leadership teams.”

Investment highlights from TVM’s medtech commercial-stage portfolio include:

• Access Vascular Inc. has developed and commercializes award-winning intravenous catheters addressing the most common and costly complications of intravenous therapy: infection, thrombosis, and phlebitis. Engineered to mimic the body’s natural chemistry, Access Vascular catheters are designed to evade foreign body response and related complications.

• Egg Medical has developed and commercializes a lab radiation protection system that dramatically reduces scatter radiation exposure during interventional angiographic procedures. During an X-ray, radiation reflects off a patient and scatters to anyone else in the room. This results in an increased risk of cancer chromosomal abnormalities, skin damage and eye injury for healthcare professionals in this field. EGGNEST™ reduces scatter radiation exposure by 91% for the entire team without interrupting the workflow.

• Emovi’s technologies and AI solutions address clinical challenges that exist through the continuum of care for patients with knee pain and pathology. The Company has developed the only FDA cleared, Health Canada licensed and CE Marked medical device to assess the 3D motion of the knee and understand what is happening in patient’s knee in order to better identify causes of symptoms and propose a successful care plan.

• Kent Imaging, a leading innovator in near-infrared tissue oxygenation imaging, develops, manufactures, and markets medical technology that supports real-time decision-making in wound care, vascular and surgical subspecialties and tracks the healing process. Kent Imaging targets limb preservation and reconstructive surgical markets – areas with clear unmet need, as non-healing wounds are a major burden to patients and the healthcare system.

• Panthera Dental, a world leader in CAD/CAM implant solutions and dental sleep appliances, has successfully combined creativity, science and know-how to bring to market its proprietary innovative technology to offer next-generation products to the dental industry as well as a novel innovation to treat sleep apnea. The Company just recently launched a new product: The Magnet-XTM, the world’s first removable magnetic implant bar offering stable forces, lateral guidance and stability and easy handling for patients with less dexterity.

About TVM Capital Life Science

TVM Capital Life Science (“TVM”) is a leading international venture capital firm focused on investing in life science innovations. The Company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care.

TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

With its late-stage investments, TVM focuses on differentiated medical technologies with commercial proof-of-concept as well as late-stage therapeutics expected to quickly reach major development or regulatory milestones. This strategy has been validated through a number of companies in both Fund I and II and the Colucid Pharmaceuticals exit.

The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

Media Relations

MC Services AG
Europe: Anne Hennecke
Tel: +49 211 529 252 22
North America: Laurie Doyle
Tel: +1 339 832 0752 Email: tvm@mc-services.eu

Montreal, Canada / Munich, Germany – 23 February 2023 – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced the promotion of Dr. Valentina Agostoni and Catello Somma to Senior Associate and Philipp Lechner to Senior Associate Corporate Finance.

“I congratulate our three talented Senior Associates. We are delighted to recognize the contributions Valentina, Catello and Philipp have made to the Company as well as their achievements with these well-deserved promotions. It is gratifying to see each of them expand their roles in our team and take on increased responsibilities,“ said Dr. Luc Marengère, Managing Partner at TVM Capital Life Science.

Dr. Hubert Birner, Managing Partner at TVM Capital Life Science, added: “These promotions underscore TVM’s commitment to professional development and talent recognition. Growing the next generation of leaders is an integral part of our strategy to position TVM for continued success. Each of these individuals brings different backgrounds, views and strengths to the team, which is essential to creating value for both our portfolio companies and investors.”

Valentina Agostoni, PhD joined TVM in December 2019, supporting the team in all stages of the investment process, particularly in deal flow screening and due diligence. Before joining TVM, she worked in preclinical development at Versantis AG and Mperia Therapeutics Inc, where she was involved in the clinical translation, from lead optimization to IND-enabling studies, of novel therapeutics across different disease areas. Valentina holds a Master’s degree in medical biotechnology from the University of Milano Bicocca and a PhD in biopharmacy and pharmaceutical technologies from the University of Paris-Saclay. She was the recipient of a Marie Curie ITN scholarship and conducted postdoctoral research in drug delivery and formulation at the Swiss Federal Institute of Technology Zurich (ETH-Zurich). She has co-authored several scientific articles and is co-inventor of 2 patents.

Catello Somma joined TVM in January 2020 and has played an integral role in deal flow generation and investment due diligence, as well as deal and exit transactions. Catello is a biotech start-up founder with more than ten years of clinical development and corporate development experience. Prior to this role, Catello worked for a mid-cap biotech where he supported the development of immuno-oncology assets, both internal and in partnership with big pharma, including the preparatory work for a successful licensing opportunity. Catello holds an MSc in molecular biology from the Università degli Studi di Napoli Federico II and an MBA with a major in finance, from MIP Politecnico di Milano.

Philipp Lechner joined TVM in July 2020. He is active in investment due diligence, deal and exit transactions as well as corporate finance and fund administration aspects of the fund. Prior to joining TVM, Philipp worked for the Global Healthcare Team at Société Générale Corporate & Investment Banking. In this role, he was involved in several cross-border M&A transactions in different healthcare industries. He holds a Master’s degree in international finance and economics from the Nuremberg Institute of Technology, with a focus on financial markets and corporate finance, and did additional business and finance studies in London, UK and Nuertingen, Germany.

About TVM Capital Life Science

TVM Capital Life Science (“TVM”) is a leading international venture capital firm focused on investing in life science innovations. The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care. TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

Media Relations

MC Services AG

Europe: Anne Hennecke
Tel: +49 211 529 252 22
North America: Laurie Doyle
Tel: +1 339 832 0752
Email: tvm@mc-services.eu

Montréal, Québec, February 21, 2023 – Esperas Pharma, Inc. (“Esperas”), a company based in Montréal, Québec, today announced a follow-on investment by TVM Capital Life Science (“TVM”) through its fund TVM Life Science Innovation I SCSp and the Fonds de solidarité FTQ (the “Fonds”). Esperas is developing the first oral Check 1 inhibitor, ESP-001 (formerly LY2880070), a compound originally discovered through a research and development program at Eli Lilly and Company, with the potential to treat certain types of cancers including high-grade serous ovarian cancer (“HGSOC”).  

“The management team of Esperas is delighted to have the continued support of our original investors. The data generated to date combined with the advancing scientific knowledge support the continued development of this promising oral Check 1 inhibitor,” said Caroline Fortier, CEO of Esperas.

With these funds, Esperas will conduct a proof-of-concept study in a genetically selected sub-population of HGSOC. In a first proof-of-concept study in HGSOC, ESP-01, combined with low-dose gemcitabine, showed a significant rate of disease control (59.3%)¹. This new trial will assess the efficacy of ESP-01 in combination with low-dose gemcitabine in patients with HGSOC with tumors expressing defined genetic profiles. The genetic assessments will be performed by Foundation Medicine through their Foundation One CDx test. Enrollment is expected to start in March 2023.

“Chk1 inhibition has a compelling rationale in this group of ovarian cancer patients with a high unmet medical need,” stated Dr. Wilson H. Miller, Director, Clinical Research Unit, Jewish General Hospital and a Principal Investigator in the study. “Initial data in ovarian cancer was very promising. Furthermore, there is no approved strategy for the treatment of ovarian cancer with the defined genetic signature in this study.”

“TVM is proud to continue its financial support of Esperas. The results generated in an initial proof-of-concept study in HGSOC show great promise for this unique anticancer agent,” said Dr. Luc Marengère, Managing Partner with TVM. “Furthermore, we are pleased to continue our collaboration with Caroline Fortier and Chantal Miklosi, who act as CEO and CFO, respectively, for Esperas.”

“This reinvestment demonstrates our commitment to finding a targeted treatment for ovarian cancer. The undertaking of clinical trials in Montréal, Toronto and Edmonton emphasizes our commitment to exploit the geographic expertise in order to improve patients’ lives everywhere. The Fonds de solidarité FTQ is proud to help Esperas in pursuing its goal of fighting one of the most life-threatening cancers in women’s health,” said Geneviève Guertin, Vice-President, Private Equity and Impact Investing, Life Sciences at Fonds de solidarité FTQ.

# # #

References

¹ESMO 2022, Miller, W.H. et al. FPN # 537: A Phase 1b/2a Study of Oral Chk1 Inhibitor LY2880070 in Combination with Low-Dose Gemcitabine in Patients with Advanced Ovarian Cancer.

About TVM Capital Life Science

TVM Capital Life Science (“TVM”) is a leading international venture capital firm focused on investing in life science innovations. The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care.

TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

With its early-stage investments, TVM follows several key principles, which include increasing capital efficiency, streamlining development timelines and soliciting buyer input at the time of investment. This strategy has been validated through successful exits such as AurKa Pharma, Inc. and Acanthas Pharma, Inc.

The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

About the Fonds de solidarité FTQ

The Fonds de solidarité FTQ invests to build a better society by channeling the savings of its 753,125 shareholders into development and risk capital investments to help Québec transition to a green economy, to a human-centred world of work, and to a healthier society. The Fonds offers businesses unsecured financing and strategic support. With $17.8 billion in net assets as at November 30, 2022, the Fonds supported more than 3,600 partner companies and over 296,000 jobs.

About Esperas Pharma, Inc.

Esperas Pharma, Inc. is a special purpose company created to develop one compound to proof-of-concept. The project is fully financed by TVM Life Science Innovation I and Fonds de solidarité FTQ (the “Fonds”). Esperas Pharma, Inc. is led by an experienced management team. The company has completed: 1) dose-escalations of ESP-001 monotherapy and in combination with gemcitabine; and 2) proof-of-concept trials in high-grade serous ovarian cancer and pancreatic cancer. A study assessing ESP-001 and low-dose gemcitabine in Ewing sarcoma is ongoing.

This press release contains forward-looking statements about TVM Life Science Innovation I SCSp investment in a clinical-stage compound for the treatment of certain types of cancers that is being developed by Esperas Pharma, Inc. It reflects TVM’s current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development. There is no guarantee that the product will receive regulatory approval, or if approved, would be commercially successful. TVM undertakes no duty to update forward-looking statements.

For additional information, please contact:

Caroline Fortier, CEO, Esperas Pharma, Inc.: esperas@mc-services.eu

Dr. Luc Marengère, Managing Partner, TVM Capital Life Science: marengere@tvm-capital.com, for media: TVM@mc-services.eu

Patrick McQuilken, Senior Advisor, Media Relations and Communications, Fonds de solidarité FTQ: pmcquilken@fondsftq.com

Recurv is the 8^th early-stage or product focused company (PFC) investment for TVM Life Science Innovation II Fund

Recurv is developing novel taxane, RP-001, against solid tumors

RP-001 delivered in nano-emulsion formulation, focusing drug delivery to tumor and sparing healthy organs

Strong efficacy in multiple pre-clinical cancer models, including multi-drug resistant tumors

Montreal, Canada / Munich, Germany – 01 February 2023 – TVM Capital Life Science (“TVM”), a leading transatlantic venture capital firm focused on investments in life sciences innovation, today announced that the company will invest up to USD 24 million in the newly formed U.S.-based biotechnology company, Recurv Pharma, Inc. (“Recurv”) with its fund TVM Life Science Innovation II SCSp (“TVM LSI II”). Recurv plans to develop to proof-of-concept a novel taxane therapy to treat solid tumors. Also, TVM will provide strategic advice to the company with Dr. Luc Marengère, Managing Partner joining the Board of Directors and Dr. Valentina Agostoni, Associate, serving as a Board Observer.  Recurv is the 8^th early-stage or project-focused company (PFC) investment for the TVM Life Science Innovation II Fund.

James E. Egan, CEO of Recurv, said: “TVM’s investment is designed to get us to a key value inflection point, namely, Phase 2a proof-of-concept, with our cancer program, RP-001. Taxanes have been a cornerstone of cancer treatment for decades, but they can come with significant side effects, and treated cancers frequently recur. We are looking to provide a safer, more efficacious treatment option that may be used in combination with immunotherapies and in a far wider range of cancers, even those resistant to current taxanes. We are excited to have TVM’s strong support and to now have the resources to further the development of this potentially game-changing molecule.”

Dr. Luc Marengère, Managing Partner of TVM, said: “TVM is excited about the potential of this novel approach which could introduce a new and safer taxane for cancers previously unresponsive to such treatment. Recurv is a perfect fit for TVM’s project-focused company investment objective – that is, to invest in first- or best-in-class product candidates with strong scientific rationale and the potential for clear differentiation from competition or added clinical value to current standard of care. TVM looks forward to working with James and the rest of the experienced team at Recurv to help them advance this important program into a clinical proof-of-concept.”

For its PFC investments, TVM has a unique arrangement with Eli Lilly and Company (“Lilly”), which is a limited partner in TVM LSI II and the earlier fund TVM LSI I, under which TVM and its PFCs have the option to engage Chorus, a full-service autonomous research and development unit within Lilly, to assist the PFC by implementing a lean and focused drug development plan, resulting in high-quality data packages to help determine proof of concept.

RP-001 is a new chemical entity (NCE) delivered in a nano-emulsion formulation that focuses the drug delivery to the tumor, sparing healthy organs. The molecule has demonstrated the ability to kill tumors even in multi-drug resistant cancers, with strong efficacy in various pre-clinical tumor models, including non-small cell lung, breast, ovarian, prostate, pancreatic and colorectal cancers. It has also been proven in preclinical models to cure tumor types that are resistant to current taxane treatments. The data have shown that RP-001 can effectively kill cancer stem cells, the cells that trigger recurrence, and toxicology studies suggest a potentially superior safety profile compared to taxanes currently on the market. Additionally, RP-001 was demonstrated to be synergistic with immune checkpoint inhibitors in a pancreatic cancer model. 

About TVM Capital Life Science

TVM Capital Life Science (“TVM”) is a leading international venture capital firm focused on investing in life science innovations.  The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care.

TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

With its early-stage investments, TVM follows several key principles, which include increasing capital efficiency, streamlining development timelines and soliciting buyer input at the time of investment.  This strategy has been validated through successful exits such as AurKa Pharma, Inc. and Acanthas Pharma, Inc.

The TVM investment team has worked together for (over) a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

About Recurv Pharma, Inc.

Recurv is a U.S.-based special purpose biotechnology company created to develop to clinical proof-of-concept one oncology compound, RP-001, a novel taxane therapy to treat solid tumors. The project is fully financed by TVM Life Science Innovation II. In various pre-clinical oncology models, the asset has shown strong efficacy data in addition to a potentially superior safety profile compared to currently available taxanes, as well as synergistic effects with immune checkpoint inhibitors.

This press release contains forward-looking statements about TVM Life Science Innovation II’s investment in a preclinical stage compound to treat certain types of cancers that Recurv Pharma is developing. It reflects TVM’s current beliefs.

Contact

TVM Capital Life Science
Dr. Luc Marengère
Managing Partner
Email: marengere@tvm-capital.com

Media Relations

MC Services AG
Europe: Anne Hennecke
Tel: +49 211 529 252 22
North America: Laurie Doyle
Tel: +1 339 832 0752
Email: tvm@mc-services.eu

Munich, Germany / Montreal, Canada – 12 January 2022 – TVM Life Science (“TVM”),
a leading International Life Sciences Venture Capital firm, today announces the formal
promotion of Dr. Sascha Berger and Dr. Alain Thibault to General Partner.  

Sascha has joined the TVM Capital Life Science team in 2016 as Principal and was
promoted to Partner in 2020. Sascha has more than 15 years professional experience.
He started his career as a management consultant at the Boston Consulting Group and later PricewaterhouseCoopers. He brings extensive experience in deal-making, life sciences venture capital, technology assessment and investment management with an academic background in chemistry and finance.

Alain joined the firm in 2020. He is a medical oncologist and an expert in first-in-man phase of oncology drug development. Prior to joining TVM, he held senior positions at Roche, Janssen, Regeneron and arGEN-X. His area of expertise includes chemotherapy, small molecule targeted therapy and biologics (monoclonal antibodies). His regulatory experience ranges from IND/IMPD-CTA write-up to IND/BLA submission and approval.

Dr. Hubert Birner, Managing Partner at TVM Capital Life Science commented, “Sascha will continue to play a pivotal role in sourcing and managing new investment opportunities for the firm, both for early stage and late-stage opportunities. Sascha already built a strong network into the transatlantic biotech and investor community. We are very pleased to announce Sascha’s promotion to General Partner today.”

Dr. Luc Marengere, Managing Partner at TVM Capital Life Science added, “Alain is a highly respected and accomplished medical oncologist with a strong track record in late pre-clinical/early clinical development in oncology where TVM is currently focusing our early-stage Project Focused Company investment strategy in partnership with Eli Lilly & Company. We are delighted to promote Alain to General Partner.”

Stefan Fischer, Managing Partner (Finance) at TVM Capital Life Science stated, “We wish both new partners continued success as they assume their new leadership responsibilities. This is based on their proven achievements, their strong expertise as well as their commitment to the values of our firm. They reflect the broad spectrum of our talent and know-how along the investment value chain and the valuable contribution to TVM’s portfolio.”

About TVM Capital Life Science

TVM Capital Life Science provides venture capital to international biopharmaceutical, medical technology, and diagnostic companies in North America and the EU. TVM follows a two-pronged strategy with a focus on early-stage and late-stage investments.

For more information please contact:

Stefan Fischer
Managing Partner (Finance), TVM Capital Life Science
fischer@tvm- capital.com
+49 89 998 992 36